Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume II.
作者信息
Malapelle Umberto, Bellevicine Claudio, Friedlaender Alex, Ciarrocchi Alessia, de Biase Dario
机构信息
Department of Public Health, University Federico II of Naples, Naples, Italy.
Oncology Service, Clinique Générale Beaulieu, Geneva, Switzerland.
出版信息
Front Endocrinol (Lausanne). 2024 Jul 29;15:1460239. doi: 10.3389/fendo.2024.1460239. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume II.社论：“下一代”技术时代甲状腺病变的分子特征：第二卷
Front Endocrinol (Lausanne). 2024 Jul 29;15:1460239. doi: 10.3389/fendo.2024.1460239. eCollection 2024.
2
Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.细针穿刺抽吸物的离心上清液为甲状腺结节的临床下一代测序提供了液体活检选择。
Cancer Cytopathol. 2019 Mar;127(3):146-160. doi: 10.1002/cncy.22098. Epub 2019 Jan 8.
3
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.用于检测甲状腺癌突变的靶向下一代测序 panel（ThyroSeq）。
J Clin Endocrinol Metab. 2013 Nov;98(11):E1852-60. doi: 10.1210/jc.2013-2292. Epub 2013 Aug 26.
4
Editorial: Molecular Characterization of Thyroid Lesions in the Era of "Next-Generation" Techniques.社论：“下一代”技术时代甲状腺病变的分子特征
Front Endocrinol (Lausanne). 2022 Jun 29;13:955185. doi: 10.3389/fendo.2022.955185. eCollection 2022.
5
Next-generation sequencing in thyroid cancer.甲状腺癌中的下一代测序
J Transl Med. 2016 Nov 21;14(1):322. doi: 10.1186/s12967-016-1074-7.
6
Utilities of Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort.术前细针穿刺活检中突变的效用对甲状腺结节管理决策的影响：来自单中心前瞻性队列研究的结果。
Thyroid. 2020 Apr;30(4):536-547. doi: 10.1089/thy.2019.0116. Epub 2020 Feb 20.
7
The Role of Molecular Testing for the Indeterminate Thyroid FNA.甲状腺细针穿刺抽吸活检结果不确定时的分子检测作用
Genes (Basel). 2019 Sep 23;10(10):736. doi: 10.3390/genes10100736.
8
Molecular testing in diagnosis of indeterminate thyroid cytology: Trends and drivers.甲状腺细胞学检查结果不明确时的分子检测：趋势和驱动因素。
Diagn Cytopathol. 2020 Nov;48(11):1144-1151. doi: 10.1002/dc.24522. Epub 2020 Jun 5.
9
Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases.具有显著肌纤维母细胞性基质成分的甲状腺乳头状癌：7 例临床病理、免疫组织化学和下一代测序研究。
Mod Pathol. 2020 Sep;33(9):1702-1711. doi: 10.1038/s41379-020-0539-7. Epub 2020 Apr 14.
10
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.甲状腺结节中 ThyroSeq v3 基因组分类器用于癌症诊断的分析性能。
Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18.
本文引用的文献
1
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
2
Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis.淋巴细胞浸润和甲状腺细胞破坏是由桥本甲状腺炎的基质和免疫细胞成分驱动的。
Nat Commun. 2022 Feb 9;13(1):775. doi: 10.1038/s41467-022-28120-2.
3
Next generation sequencing in cytology.细胞学中的下一代测序。
Cytopathology. 2021 Sep;32(5):588-595. doi: 10.1111/cyt.12974. Epub 2021 Apr 1.
4
Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel.迈向针对甲状腺细针穿刺活检结果未明的本地化检测解决方案：一种新型定制DNA测序二代测序（NGS）检测板的验证
J Clin Pathol. 2022 Jul;75(7):465-471. doi: 10.1136/jclinpath-2021-207429. Epub 2021 Mar 31.
5
Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation.桥本甲状腺炎：发病机制、诊断方案、治疗策略及潜在恶变更新。
Autoimmun Rev. 2020 Oct;19(10):102649. doi: 10.1016/j.autrev.2020.102649. Epub 2020 Aug 15.
6
Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel.使用二代测序定制多基因panel对实体瘤进行分子诊断
Diagnostics (Basel). 2020 Apr 23;10(4):250. doi: 10.3390/diagnostics10040250.
7
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology.甲状腺结节不典型细针抽吸细胞学检查中 ThyroSeq v3 基因组分类器的临床验证。
Cancer Cytopathol. 2019 Apr;127(4):225-230. doi: 10.1002/cncy.22112. Epub 2019 Feb 27.
8
Thyroglobulin measurement in the management of patients with differentiated thyroid cancer.甲状腺球蛋白在分化型甲状腺癌患者管理中的应用。
Crit Rev Clin Lab Sci. 2018 May;55(3):205-218. doi: 10.1080/10408363.2018.1450830. Epub 2018 Mar 16.
9
The 2017 Bethesda System for Reporting Thyroid Cytopathology.2017 年甲状腺细胞病理学报告的贝塞斯达系统。
Thyroid. 2017 Nov;27(11):1341-1346. doi: 10.1089/thy.2017.0500.
10
Non-invasive diagnosis of papillary thyroid microcarcinoma: a NMR-based metabolomics approach.甲状腺微小乳头状癌的非侵入性诊断：基于核磁共振的代谢组学方法。
Oncotarget. 2016 Dec 6;7(49):81768-81777. doi: 10.18632/oncotarget.13178.
Zotero 插件